Skip to content
Biodatica
Start free

International Extranodal Lymphoma Study Group (IELSG)

Yvoir

OncologyPhase III
Compare Sign in to watch

What changed

Phase II trial registered: MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

3mo agoTrial registeredApr 8, 2026Source filing (opens the source filing in a new tab)

Momentum

78no change

Momentum 78 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

408 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    May 21, 2024

    Splenic Marginal Zone Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: International Extranodal Lymphoma Study Group (IELSG) · Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

    ClinicalTrials.gov · NCT05735834 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Dec 1, 2020

    Marginal Zone Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: International Extranodal Lymphoma Study Group (IELSG) · FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

    ClinicalTrials.gov · NCT04333524 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Sep 27, 2019

    Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: International Extranodal Lymphoma Study Group (IELSG) · MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

    ClinicalTrials.gov · NCT03697512 (opens the source filing in a new tab)

  4. Trial

    Study registered

    Mar 1, 2018

    Follicular Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Oncology Institute of Southern Switzerland · Personalized Risk Stratification Model of Follicular Lymphoma Patients

    ClinicalTrials.gov · NCT03436602 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources